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Abstract 
BACKGROUND: Inflammation plays a major role in the initiation, destabilization and the progression of 
atherosclerosis. High Sensitivity C-Reactive Protein (hs-CRP) reflects active systemic inflammation and have 
shown to be a strong predictor of future cardiovascular events. 
AIM: The purpose of this study was to determine the role of High Sensitivity C-Reactive Protein (hs-CRP) 
independent for atherosclerosis severity prediction and to find out which factors largely is affecting hs-CRP level 
in dyslipidemia patient. 
METHODS: A total of 388 patients (267 dyslipidemia, 121 controls) were enrolled in this study. We investigated 
whether plasma hs-CRP is associated with atherosclerosis severity that was quantiﬁed by ankle-brachial index 
(ABI) and Doppler ultrasound. Related risk factor that influence hs-CRP levels in patients with dyslipidemia 
included determination of age, gender, diabetes, smoking, hypertension, total cholesterol, TG, LDL, HDL, and 
fasting glucose. 
RESULTS: Data showed a significant association between hs-CRP concentration level and the severity of 
atherosclerosis (p < 0.01). Univariate analysis showed that fasting plasma glucose, triglyceride, and BMI were 
signiﬁcantly positively correlated with hs-CRP levels. Whereas, HDL cholesterol was negatively correlated with 
hs-CRP levels. Multivariate regression analysis using model 1 and 2, showed that in determining hs-CRP levels, 
triglyceride and BMI were taking a big role. 
CONCLUSION: Hs-CRP correlates with extent of atherosclerosis, and high triglyceride and BMI is closely 
associated with high hs-CRP levels in patients with dyslipidemia. 
 
 
 
 
 
 
 
Introduction 
 
Recent study has provided strong evidence 
for the importance of primary or secondary 
inflammatory processes in the pathogenesis of 
atherosclerosis [1], [2]. C-reactive protein, as a marker 
of chronic inflammation have been found in patients 
with peripheral arterial disease, this can be interpreted 
as a systemic reaction to inflammatory processes in 
the vessel wall [3], [4]. The mechanism of 
inflammation plays a central role in all phases of 
atherosclerosis, from the initial recruitment of 
circulating leukocytes to the arterial wall until the 
rupture of the plaque. 
High Sensitive C-Reactive Protein (hs-CRP) 
has long been studied as one of the inflammatory 
biomakers with high sensitivity in several diseases, 
especially those related to CHD [2], [3]. Hs-CRP level 
has been reported being associated with carotid 
atherosclerosis in patients with type 2 diabetes 
mellitus [5], [6], and has been suggested being a 
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useful marker to predict an accelerated atherosclerotic 
process. There for we investigate the possible 
association between serum hs-CRP with 
atherosclerosis severity. hs-CRP levels were also 
shown associated with increased cardiovascular risk 
[7], [8], [9], [10]. Several new pharmacological 
approaches have been discovered to reduce hs-CRP 
levels [11], [12]. We examined about the accumulation 
of several atherosclerosis related risk factors 
influenced serum hs-CRP levels and tested in patients 
with dyslipidemia to assess which factor that took a 
big role in influencing hs-CRP levels. 
 
 
Material and Methods 
 
The study was carried out in a cross-sectional 
manner, with purposive sampling. We enrolled 267 
sample patients with dylipidemia in line with inclusion 
criteria and exclusion criteria in the present study who 
visited Sanjiwani Hospital Gianyar on January-June 
2018. The control group consisted 121 patients 
matched the aged and without dyslipidemia diagnosis. 
Traditional risk factors used in multivariable analyses 
included: age, gender, diabetes, smoking, 
hypertention, total cholesterol, TG, LDL, HDL, and 
fasting glucose. We excluded patients with the 
following diseases: autoimmune disease, acute 
inﬂammatory disease, malignancy, severe liver 
dysfunction, severe renal dysfunction (male: 
creatinine Cre ≥ 1.2 mg/dL; female: Cre ≥ 1.0 mg/dL), 
severe hypertriglyceridemia (triglyceride [TG] ≥ 400 
mg/dL), using steroid and/or immunosuppressive 
agents, and pregnant patients. The Faculty of 
Medicine Udayana University ethics committee 
approved the study protocol (No. 34 / UN14.16 / 
2018), and informed consent was obtained from each 
patient by showing it and with a full explanation of the 
study. 
 
Determination of Atherosclerosis severity.  
Vascular Doppler MD2 Hungleight with an 
8MHz transducer and a random-zero 
sphygmomanometer with the cuff positioned just 
proximal to the elbow/malleoli was used to measure of 
ankle-brachial index (ABI) and In Doppler Ultrasound 
each lesion was visually estimated for percent 
diameter stenosis rounded to the nearest 10%. No 
atheroscleoris: ABI > 0.9 and stenosis < 10%, Mild to 
moderate atherosclerosis: ABI 0.7-0.9 and stenosis 
(10% to 60%), severe atherosclerosis ABI < 0.7 and 
stenosis (70% to 100%). 
 
Laboratory Analysis 
C-reactive protein was measured by an 
enzyme immunoassay (Abbott Diagnostics, Abbott 
Park, Illinois), the detection limit of the assay was 0.2 
mg/liter. For clinical practice, a threshold level of 5.0 
mg/liter is recommended. Serum concentration of 
trygliceride, glucose and cholesterol ware measure 
using an autoanalyzer (Hitachi/Boehringer Mannheim, 
Germany) 
 
Statistical Analysis 
The Mann – Whitney U-test was used to 
compare two groups. The Kruskal–Wallis test was 
used to carry out overall group comparisons, and the 
Steel – Dwass test was used to carry out between-
group comparisons. Spearman’s rank correlation was 
carried out to study the correlation between hs-CRP 
levels and clinical parameters. Multivariate regression 
method was used to analyze the factors 
independently contributing to serum hs-CRP levels. 
All data will analyses performed using SPSS for 
Windows, version 20.00 (SPSS Inc., Chicago, Illinois) 
with significance (*P < 0.05, **P < 0.01). 
 
 
Results  
 
A total of 388 subjects were enrolled this 
study that devided to controls and patients’ group. The 
main clinical and laboratory findings of patients and 
control are shown in Table 1. The mean age of 
patiens was about 8 years hinger than controls. In the 
patient’s groups, there were fewer female, but more 
male, smokers, diabetes, hypertension, and high level 
of hs- CRP.  
Table 1: Baseline Characteristics of Patients and Controls 
 Controls Patients 
Mean ± SD 90%-range Mean ± SD 90%-range 
Age (years) 42.5 ± 7.8 32.7-62.7 56.2 ± 9.1 39.4-70 
BMI 25.7 ± 4.0 20.8-33.4 26.8 ± 3.7 21.1-3.33 
Smokers (%) 22 - 51 - 
Diabetes (%) 6 - 21 - 
Hypertension (%) 33 - 57 - 
Male (%) 56 - 63 - 
Female (%) 44 - 37 - 
Total cholesterol (mg/dl) 160 ± 23.2 150.2-190.4 240 ± 43 174-317 
LDL 
Cholesterol (mg/dl) 
70 ± 26.7 60.9-100.6 170 ± 38 112-237 
Triglyceride (mg/dl) 120 ± 13.2 100.2-150.4 150 ± 45 105-195 
HDL 
Cholesterol (mg/dl) 
45 ± 10.6 30.7-60 44.1 ± 12.0 27.0 – 66.5 
Fasting plasma glucose 100.6 ± 8.9 90.5-102 120 ± 18 102-138 
Hs-CRP (g/ml) 0.87 ± 1.34 0.00-3.65 1.46 ± 1.62 0.80 – 5.20 
 
Correlations of hs-CRP with atheroclerosis 
 severity 
Plasma concentrations of hs-CRP in controls 
grop were higher than patients’ group (Table 2). 
There’s a significant hs-CRP level between controls 
and those who diagnose with atherosclerosis (p < 
0.01). Level of hs-CRP in severe atherosclerosis was 
significantly higher than mild/moderate 
atherosclerosis, so there’s was association between 
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hs-CRP concentration level and the severity of 
atherosclerosis. 
Table 2: Level of hs-CRP in dyslipidemia patient and control 
 Group n hs-CRP g/ml p 
Mean ± SD Median 
Controls 121 1.06 ± 1.63 0.48  
No Atherosclerosis 65 1.56 ± 1.55 0.75 0.132 
Mild/Moderate Atherosclerosis 105 1.52 ± 1.77 0.56 0.005
**
 
Severe Atherosclerosis 97 1.83 ± 1.60 1.31 0.001
**
 
 
 
Related risk factor in hs-CRP serum levels 
Univariate and multivariate analysis were 
used to examine and estimate the influence of clinical 
parameters which largely influencing the hs-CRP 
serum levels. As shown in Table 3, in a univariate 
analysis, fasting plasma glucose, triglyceride, an BMI 
were signiﬁcantly positively correlated with hs-CRP 
levels. Whereas, HDL cholesterol was negatively 
correlated with hs-CRP levels. Then a multivariate 
regression analysis, using fasting plasma glucose, 
triglyceride, BMI, and HDL cholesterol as independent 
variables (model 1) all of which were signiﬁcantly 
associated with hs-CRP in a univariate analysis, was 
carried out to determine the independent factors 
contributing to serum hs-CRP levels. As shown in 
Table 3, independent factors determining hs-CRP 
levels were triglyceride and BMI. Furthermore, a 
multivariate regression analysis including age and 
sex, as well as fasting plasma glucose, triglyceride, 
BMI, HDL cholesterol, as independent variables 
(Table 3, model 2), showed that independent factors 
for determining hs-CRP levels were sex, triglyceride, 
and BMI. 
Table 3: Correlation of serum hs-CRP and a variety of clinical 
parameters and multivariate regression analysis to determine 
the independent factors contributing to hs-CRP levels in all 
subjects 
hs-CRP Univariate Multivariate Model 1 Multivariate Model 2 
Related Risk Factor  p t p t p 
Total cholesterol 0.056 ns     
LDL cholesterol 0.069 ns     
Triglyceride 0,257 < 0.0001 2.98 0.0029 3.03 0.0031 
HDL cholesterol -0.245 0.001 -1.16 ns -1.31 ns 
Fasting plasma glucose 0.160 0.009 1.21 ns 0.89 ns 
BMI 0.254 < 0.0001 3.00 0.0302 2.40 0.0275 
Hypertension 0.060 ns     
Diabetes -0.158 ns     
Smoking 0.055 ns     
Age 0.145 ns   0.03 ns 
Genders (male 1, female 2)     2.04 0.0321 
Triglyceride, BMI, HDL cholesterol, fasting plasma glucose (model 1); triglyceride, BMI, 
HDL cholesterol, fasting plasma glucose, age and gender (model 2); BMI: Body Mass 
Index; LDL: Low Density Lipoproteins; HDL: High Density Lipoproteins. 
 
 
 
Discussion 
 
Our study clearly shows that there was an 
association between hs-CRP concentration and the 
severity of atherosclerosis. The value of hs-CRP in 
predicting atherosclerosis is noticeable in all ranges of 
atherosclerosis severity. Extensive atherosclerosis is 
relatively high risk regardless of hs-CRP levels. Some 
previous studies have shown a correlation between 
hs-CRP and the presence of atherosclerosis [13], 
whereas others have not found a correlation [14]. 
Although our result is consistent with hs-CRP being a 
marker of atherosclerosis, our data give no 
explanation about underlying process. Various 
hypotheses to explain the possible mechanism of 
which hs-CRP increasing the atherosclerotic risk have 
been proposed [15]. It has been thought that the 
development of atherosclerosis was led by serum hs-
CRP level [5], [6], [7], [8], [9], [10], [11], [12]. C-
reactive protein previously has been proposed to 
correlate with the extent of atherosclerosis [14]. Lower 
profile plaques were shown as numerous than 
“significant stenoses” in some studies and were 
statistically more likely to lead to plaque rupture than 
the relatively few lesions of > 70% stenosis [16]. 
Therefore, an elevated hs-CRP was possibly 
representing a more diffuse process of coronary 
atherosclerosis with a higher total plaque burden. If 
so, the predictive value of CRP would be considerably 
less after adjustment for extent of disease (total 
number of lesions) assessed by coronary 
angiography. So that the predictive value of hs-CRP 
must be adjusted for measures of all visible 
atherosclerotic plaques on angiography to exclude the 
possibility of an elevated CRP. On the other hand, if 
CRP levels primarily represent plaque properties (i.e., 
inﬂammation, instability), knowledge of CRP levels 
would continue to be useful even in the presence of 
angiographic assessment of plaque burden (extent / 
severity). Similarly, CRP and coronary calcium score 
(assessed by ultrafast computed tomography) may 
have independent and additive prognostic value, but 
this has not been extensively evaluated.  
Hs-CRP proved to be the strongest and most 
significant predictor of the risk of future cardiovascular 
events [17]. Even though several new 
pharmacological approaches have been introduced to 
reduce the hs-CRP levels [15]. [18], [11], [3], there are 
still many cardiovascular diseases all over the world. 
Hs-CRP and the ratio of total cholesterol to HDL 
cholesterol were found to be independent predictors 
of risk in models in which women were matched for 
smoking status and age or in models that included 
further adjustments for body-mass index, 
hypertension, diabetes, and parental history of 
premature coronary artery disease [11]. In our present 
study, we found that independent factors for 
determining hs-CRP levels are triglyceride, BMI, and 
fasting plasma glucose. Thus, it is important to 
undergo a strict management of atherosclerosis 
related risk factors, which were triglyceride, fasting 
plasma glucose and BMI, to reduce serum hs-CRP 
levels in patients with dyslipidemia. Multivariate 
regression analysis showed that triglyceride and BMI 
were independent risk factors determining hs-CRP 
levels (Table 3). These results suggest that high 
triglyceride and high BMI are closely associated with 
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high serum hs-CRP levels in patients with 
dyslipidemia. 
Quantiﬁcation of atherosclerosis ﬁndings was 
limited to the visual interpretation of the attending 
cardiologist, which is representative of “real world” 
practice. Intravascular ultrasound could be expected 
to give increased measures of atherosclerotic burden 
by identifying “intramural plaques,” although this 
would be impractical to apply routinely. 
The significant diﬀerences between hs-CRP 
concentrations in our study, depending on the severity 
of atherosclerosis, give some evidence for a possible 
function of hs-CRP protein as an epidemiological risk 
marker. They support the hypothesis of a causal 
relationship between an acute phase reaction and the 
pathogenesis of atherosclerosis in coronary arteries 
and other parts of the arterial vessel system. High 
triglyceride and BMI is closely associated with high 
hs-CRP level in patients with dyslipidemia. We should 
consider this point in practical medicine, and thus the 
data in the present study results would provide 
important information from a clinical point of view. 
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